Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
Catamaran joins the CAR-NK fleet, raising $42m in first roundCatamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its Share XCatamaran joins the CAR-NK fleet, raising $42m in first roundhttps://pharmaphorum.com/news/catamaran-joins-the-car-nk-fleet-raising-42m-in-first-round/
Sanofi to acquire Kiadis and NK cell tech for $353 millionSanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) Share XSanofi to acquire Kiadis and NK cell tech for $353 millionhttps://pharmaphorum.com/news/sanofi-to-acquire-kiadis-and-nk-cell-tech-for-353-million/
Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
Patient-to-Patient Supply for Cell Immunotherapies SummitAchieving Standardization & Operational Excellence in Vein-to-Vein Supply As an increasing number of candidates enter the clinic and Share XPatient-to-Patient Supply for Cell Immunotherapies Summithttps://pharmaphorum.com/events/patient-to-patient-supply-for-cell-immunotherapies-summit/
2nd Macrophage-directed Therapies SummitHarnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Share X2nd Macrophage-directed Therapies Summithttps://pharmaphorum.com/events/2nd-macrophage-directed-therapies-summit/
